Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tibotec's Intelence approved in Europe

This article was originally published in Scrip

Executive Summary

Tibotec's Intelence (etravirine) has been approved by the European Commission for the treatment of HIV-1 in antiretroviral treatment-experienced adults. Tibotec said that Intelence will be available across the EU, but said that the timing of its launch would be dependent on pricing and reimbursement negotiations in individual countries. Intelence, a non-nucleoside reverse transcriptase inhibitor, was approved in the US in January and received a positive opinion from the EU's CHMP in June (Scrip Online, June 27th, 2008).

You may also be interested in...



Targacept/AstraZeneca Alzheimer's hope fails in Phase II

Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.

Amgen reveals more details of denosumab's fracture benefit

Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.

GSK and Xenoport file restless legs drug Solzira in US

GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.

Topics

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel